tailieunhanh - Báo cáo y học: " Acceptability of cancer chemoprevention trials: impact of the design"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: Acceptability of cancer chemoprevention trials: impact of the design. | Int. J. Med. Sci. 2008 5 244 International Journal of Medical Sciences ISSN 1449-1907 2008 5 5 244-247 Ivyspring International Publisher. All rights reserved Research Paper Acceptability of cancer chemoprevention trials impact of the design Anne-Sophie Maisonneuve 12 Laetitia Huiart 1 2 Laetitia Rabayrol 1 2 Doug Horsman 3 Remi Didelot 4 Hagay Sobol 1 2 Francois Eisinger 1 2 3 H 1. Institut Paoli-Calmettes Department of Oncogenetics Prevention and Screening Marseille France FE ASM LH LR HS 2. INSERM U 599 Marseille France FE ASM lH LR HS 3. Hereditary Cancer Program British Colombia Cancer Agency FE DH 4. Local Administration of the National Health Insurance System - Centre d Examen de Sante CESAM 13 Marseille France RD H Correspondence to Francois Eisinger Institut Paoli-Calmettes - INSERM UMR 599 232 Bd St Marguerite 13009 Marseille France. Tel 33 491 22 35 41 fax 33 491 22 38 57 Received Accepted Published Background Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk benefit balance is at best achieved through randomized clinical trials. Methods At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials. Results Among the 851 respondents 228 agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation acceptability rate for lung cancer and for breast cancer . In these volunteers short-term trials 1 year reached a high level of acceptability and for lung and breast cancer prevention respectively. In contrast long-term trials 5 years or more were far less acceptable for lung cancer OR CI95 and for breast cancer OR